Moberg Pharma AB: Clinical Trials

5 completed. 5 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
An Open,Single-centre Pilot Study of Efficacy and Safety of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO) MOB015B - Distal Subungual Onychomycosis	Phase 2	Completed	Moberg Pharma AB		2012-12-01	2014-09-22
Efficacy and Safety of Two Treatment Regimens of Topical MOB015 in Adults With Distal Subungual Onychomycosis MOB015 - Onychomycosis	Phase 2	Completed	Moberg Pharma AB	250	2010-12-01	2012-10-25
Two Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp K40a, K40b, Placebo - Seborrhoeic Dermatitis of the Scalp	Phase 2 / Phase 3	Completed	Moberg Pharma AB	98	2007-02-01	2010-06-04
Assessment of the Effects on Barrier Impairment, Clinical Features and Bacterial Colonization of Topical Formulations in Patients With Atopic Eczema; a Phase IIa, Single-center, Randomized, Observer-blind Study K201 - Atopic Dermatitis	Phase 1 / Phase 2	Completed	Moberg Pharma AB			2009-11-06
Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head Imiquimod (topical use) - Actinic Keratosis	Phase 2	Completed	Moberg Pharma AB			2013-06-26